Employers just priced 2027. A lot of Americans are about to start shopping for care abroad.

Health benefit costs are set to rise more than at any point since 2003, and employers are explicitly planning to move the increase onto workers. That changes who counts as a price-sensitive patient — and it arrives before the infrastructure that would make shopping across borders safe.

The numbers landed in the first week of September, and they were worse than the industry expected.

Marsh, formerly Mercer, surveyed more than 1,800 US employers and projects total health benefit cost per employee will rise 8.2 per cent in 2027, the steepest increase since 2003. That figure already assumes employers act. Left alone, they said, their current plans would cost 11 per cent more. Aon puts the increase at 9.5 per cent, carrying average cost per employee past $19,000. The Business Group on Health projects a 9.2 per cent median before plan changes.

The part that matters for patients is what employers intend to do about it. Fifty-nine per cent told Marsh they plan cost-cutting changes for 2027, including plan design changes such as higher deductibles. Around two-thirds of employers with 500 or more workers expect to raise the employee share of premiums. Employees are already paying roughly 10 per cent more out of pocket in 2026 than in 2025, about $2,167 on average. On the individual market, the expiry of the enhanced ACA subsidies has driven premiums up sharply since January.

This is not a story about national health expenditure, which reached $5.3 trillion in 2024, or 18 per cent of GDP, at $15,474 a head. Those are aggregates, and aggregates do not change anyone's behaviour. What changes behaviour is the deductible on a specific procedure in a specific year.

2027 is the year a large number of insured Americans will discover that a planned operation carries a personal cost that looks less like a copay and more like a car.

The comparison patients actually run

At that point a question that used to sound eccentric becomes arithmetic.

It is not "is US healthcare more expensive than healthcare abroad." Everyone knows the answer. It is narrower and more practical: what will this procedure cost me, after my deductible and coinsurance and whatever my plan excludes, against the total cost of getting appropriate care somewhere else?

Note the word total. Not the procedure price. The relevant unit is the entire episode: consultations, diagnostics, the procedure, implants, medications, accommodation, airfare for the patient and a companion, time away from work, rehabilitation, and any follow-up after returning. A quoted package that covers the operation and nothing else is not a price. It is a fragment of one.

Get that unit wrong and the arithmetic inverts quickly. A $12,000 procedure abroad against $40,000 at home looks like a $28,000 saving until an unplanned readmission at home costs $30,000 and no one has agreed to pay for it.

The supply side is already moving, and it is moving in one direction

While US cost-sharing rises, capacity elsewhere is expanding faster than most American benefits managers realise.

South Korea received 2.01 million foreign patients in 2025, a 71.9 per cent increase over 2024, according to its Ministry of Health and Welfare. Among them were 173,363 Americans, up 70.4 per cent in a single year. India recorded 644,387 foreign arrivals for medical purposes in 2024 and has set a national target of 10 million medical value travellers annually. Thailand, Turkey, Mexico, Singapore and the UAE are all competing for the same patients.

But Korea's composition is the more instructive number, and it cuts against the easy narrative. Roughly 63 per cent of those patients went for dermatology and 11 per cent for cosmetic surgery. Nearly 88 per cent were treated at clinic-level institutions rather than hospitals, and 87 per cent of the volume sat in Seoul.

In other words, the fastest-growing segment of cross-border care is low-acuity, elective and largely aesthetic. That is the category where the stakes of a wrong decision are lowest, the procedure is well defined, and the patient does not much need a medical opinion to know what they want.

None of that describes the patient facing a cardiac procedure, a spinal fusion, a cancer treatment plan or a joint replacement in 2027 because their deductible moved. That patient is making a genuinely clinical decision, and the infrastructure supporting the dermatology traveller does nothing for her.

Healthcare is not an airline ticket

The internet is very good at converting complicated products into price comparisons, and that model works for standardised goods. Two seats on the same route differ by schedule, stops and baggage. Once those are fixed, price decides.

A $12,000 cardiac procedure and a $45,000 one may not be the same product at all. The underlying diagnosis may differ. The proposed intervention may differ. One surgeon may have done the operation four hundred times and the other forty. Intensive care capability, infection control and complication management differ between institutions in ways no website exposes. One quote includes the implant, the other doesn't.

And there is a possibility the price comparison cannot detect at all, which is that the patient does not need the proposed procedure.

That is why price has to come last rather than first. Before a patient can evaluate a quote, someone has to answer whether the diagnosis is right, whether the treatment is necessary, what alternatives exist, whether this surgeon is appropriate for this case, what the quote actually covers, what happens if there is a complication, and who is responsible once the patient is home. Only after those are settled does a number mean anything.

Which suggests the first thing a global healthcare market should sell is not a destination. It is an independent specialist review of the medical decision itself, conducted before any destination is chosen, and structured so the reviewer has no stake in the answer.

Sometimes that review will conclude that travelling makes sense. Sometimes it will identify a diagnostic gap, or a less invasive option. And sometimes it will conclude that the patient can be treated appropriately at home, which is a valuable answer even though it produces no trip.

The employers are the ones to watch

The consumer story is the visible one. The consequential one is institutional, and it is already forming inside the same survey.

Marsh reports that 12 per cent of large employers expect to offer variable copay plans in 2027, rising to 18 per cent among those with 20,000 or more workers. These designs lower a member's cost when they use designated high-performing providers for specific services. Employers, in other words, are building steerage machinery, and domestic centres-of-excellence programmes with travel benefits have existed for years.

International centres of excellence are a configuration of that same machinery. The economics are straightforward once a plan sponsor is covering airfare and lodging and still paying materially less for the episode.

But an institutional purchaser has to clear a bar no individual can. It needs verified provider selection, measured outcomes rather than marketing claims, genuinely bundled pricing, defined coverage for complications on both sides of the border, enforceable data protection, and a contractual answer to who manages the patient after she lands.

It also needs one thing that is easy to skip. An independent clinical review, paid the same regardless of its conclusion, gating entry to the programme. Without it, an employer that steers members abroad has not purchased better care. It has exported a utilisation problem to a jurisdiction where it has less visibility and no recourse, and it will find out slowly.

If those pieces are put in place, this stops being tourism and becomes cross-border healthcare purchasing, which is a different industry with different obligations.

What is actually being removed

For most of modern medicine, geography set the boundary of a patient's options. You were treated by the hospitals within driving distance and inside your network.

Digital medicine has weakened the informational half of that boundary. The 2027 cost-sharing numbers are weakening the economic half. Both of those constraints were arbitrary, and losing them expands what patients can consider.

What has not been removed, and cannot be, is the requirement for judgement. The easier it becomes to buy healthcare across a border, the more valuable it becomes to establish first whether the purchase should be made at all.

Patients are consumers. Healthcare is not a commodity. The next few years will test how well an industry can hold both of those at once.

Chida Khatua is the founder of Healing Tourist (healingtourist.com), a medical second-opinion platform that pays panel specialists a fixed review fee whether or not the conclusion supports travelling for treatment.